Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world... Show more
ACADIA Pharmaceuticals is a San Diego-based biopharmaceutical company focused on central nervous system disorders and rare diseases, anchored by two commercial products: NUPLAZID for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE, the first FDA-approved treatment for Rett syndrome. The third quarter of 2026 mattered to investors because it tested whether DAYBUE's new STIX formulation and an emerging European launch could extend the company's growth beyond its established NUPLAZID base. With the stock having lagged in prior quarters and SG&A (selling, general and administrative) spending rising to support an expanded sales force, this report offered a crucial read on whether commercial momentum could translate into durable top-line growth and improving profitability.
ACADIA posted third quarter 2026 total revenue of $342 million, up 22% year over year on a non-GAAP adjusted basis and ahead of the consensus estimate of approximately $332 million. The growth was driven by both franchises. DAYBUE net sales reached a record $140 million, a 39% increase, with nearly all of the growth coming from volume as uptake of the DAYBUE STIX formulation expanded — more than half of U.S. DAYBUE patients were using STIX by quarter-end. NUPLAZID net sales were $202 million, up 12% year over year on an adjusted basis, supported by healthy new-to-brand prescription trends.
On the bottom line, GAAP net income was $54 million, or $0.31 per diluted share, compared with $72 million, or $0.42 per share, in the prior-year period. The decline reflected a $26.9 million income tax expense versus a $27.2 million income tax benefit a year earlier, along with higher SG&A spending of $159 million, up from $133 million. Research and development (R&D) expenses declined to $76 million from $88 million. The company ended the quarter with $976 million in cash, cash equivalents, and investments.
Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a useful companion for earnings-focused research. Consider exploring the AI Screener to surface ideas aligned with your own criteria.
The third quarter report drew a measuredly positive response, with ACAD shares trading modestly higher in after-hours activity as investors weighed the revenue beat and raised DAYBUE guidance against a year-over-year decline in GAAP net income. Sentiment centered on the durability of DAYBUE's growth, the encouraging adoption of its STIX formulation, and the significance of European Commission approval, which made DAYBUE the first and only approved treatment for the neurobehavioral symptoms of Rett syndrome in the European Union. The company's early October commercial launch in Germany — where it can price freely during reimbursement negotiations — gave investors a concrete near-term catalyst to monitor alongside continued NUPLAZID execution.
Looking ahead, investors are likely to focus on how quickly DAYBUE's European launch converts initial physician interest into sustained commercial sales. Management plans to submit reimbursement dossiers for key launch countries before year-end, and the pace of those negotiations will shape how rapidly international revenue contributes to the top line.
In the United States, the trajectory of DAYBUE STIX adoption — including patient restarts and new patient starts — remains a central growth driver, while the company reiterated its $700 million sales ambition for DAYBUE by 2028. A recently announced patent allowance extends U.S. exclusivity into 2041, supporting the franchise's longer-term outlook.
On the NUPLAZID side, watch whether the expanded field force converts stronger intent-to-prescribe signals into new-to-brand prescription growth through late 2026 and into 2027. Pipeline catalysts also loom, including clinical readouts across Alzheimer's disease psychosis and other programs, which could broaden the company's growth story beyond its two marketed products. As always, near-term results will hinge on execution rather than any single headline.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a developer of pharmaceuticals drugs for treatment of central nervous system disorders
Industry Biotechnology